EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

The Role of Fascin-1 in Human Urologic Cancers: A Promising Biomarker or Therapeutic Target?

Naibin Zhang, Qiang Bian, Yankun Gao, Qianqian Wang, Ying Shi, Xiangling Li, Xiaolei Ma, Huiyuan Chen, Zhankui Zhao, Honglian Yu iD

Technology in Cancer Research & Treatment · 2023

DOI: 10.1177/15330338231175733 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Technology in Cancer Research & Treatment, 2023. Verfasst von Naibin Zhang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry, Jining Medical University, Jining, Shandong, People's Republic of China. Hauptthemen laut MEDLINE: Biomarkers, Tumor, Carrier Proteins, Urinary Bladder Neoplasms, Prostatic Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 123 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Natural Science Foundation of Shandong Province, College Students’ Innovative Entrepreneurial Training Plan Program of Jining Medical University, Research Support Foundation of Jining Medical University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Human cancer statistics show that an increased incidence of urologic cancers such as bladder cancer, prostate cancer, and renal cell carcinoma. Due to the lack of early markers and effective therapeutic targets, their prognosis is poor. Fascin-1 is an actin-binding protein, which functions in the formation of cell protrusions by cross-linking with actin filaments. Studies have found that fascin-1 expression is elevated in most human cancers and is related to outcomes such as neoplasm metastasis, reduced survival, and increased aggressiveness. Fascin-1 has been considered as a potential therapeutic target for urologic cancers, but there is no comprehensive review to evaluate these studies. This review aimed to provide an enhanced literature review, outline, and summarize the mechanism of fascin-1 in urologic cancers and discuss the therapeutic potential of fascin-1 and the possibility of its use as a potential marker. We also focused on the correlation between the overexpression of fascin-1 and clinicopathological parameters. Mechanistically, fascin-1 is regulated by several regulators and signaling pathways (such as long noncoding RNA, microRNA, c-Jun N-terminal kinase, and extracellular regulated protein kinases). The overexpression of fascin-1 is related to clinicopathologic parameters such as pathological stage, bone or lymph node metastasis, and reduced disease-free survival. Several fascin-1 inhibitors (G2, NP-G2-044) have been evaluated in vitro and in preclinical models. The study proved the promising potential of fascin-1 as a newly developing biomarker and a potential therapeutic target that needs further investigation. The data also highlight the inadequacy of fascin-1 to serve as a novel biomarker for prostate cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Biomarkers, TumorCarrier ProteinsUrinary Bladder NeoplasmsProstatic NeoplasmsCarcinoma, Renal CellKidney NeoplasmsHumansMaleMolecular Targeted TherapyLymphatic MetastasisMicrofilament Proteins

Stichwörter der Autor:innen

biomarkerfascin-1lncRNApathogenesissignalingurologic cancers

Substanzen

Biomarkers, TumorCarrier ProteinsFSCN1 protein, humanMicrofilament Proteins

Autor:innen und Institutionen

  • Department of Biochemistry, Jining Medical University, Jining, Shandong, People's Republic of China.
  • Clinical Medical College, Jining Medical University, Jining, Shandong, People's Republic of China.
  • Department of Pathophysiology, Weifang Medical University, Weifang, Shandong, People's Republic of China.
  • College of Radiology, Shandong First Medical University, Jinan, Shandong, People's Republic of China.
  • The Affiliated Hospital of Jining Medical University, Jining Medical University, Jining, Shandong, People's Republic of China.
  • Collaborative Innovation Center, Jining Medical University, Jining, Shandong, People's Republic of China.

ORCID-Profile: Honglian Yu

Förderung

  • Natural Science Foundation of Shandong Province
  • College Students’ Innovative Entrepreneurial Training Plan Program of Jining Medical University
  • Research Support Foundation of Jining Medical University

Zitieren

APA

Zhang, N., Bian, Q., Gao, Y., Wang, Q., Shi, Y., Li, X., Ma, X., Chen, H., Zhao, Z., & Yu, H. (2023). The Role of Fascin-1 in Human Urologic Cancers: A Promising Biomarker or Therapeutic Target?. Technology in Cancer Research & Treatment. https://doi.org/10.1177/15330338231175733

Vancouver

Zhang N, Bian Q, Gao Y, Wang Q, Shi Y, Li X, et al. The Role of Fascin-1 in Human Urologic Cancers: A Promising Biomarker or Therapeutic Target?. Technology in Cancer Research & Treatment. 2023. doi:10.1177/15330338231175733

BibTeX
@article{Zhang2023,
  author = {Zhang, Naibin and Bian, Qiang and Gao, Yankun and Wang, Qianqian and Shi, Ying and Li, Xiangling and Ma, Xiaolei and Chen, Huiyuan and Zhao, Zhankui and Yu, Honglian},
  title = {The Role of Fascin-1 in Human Urologic Cancers: A Promising Biomarker or Therapeutic Target?},
  journal = {Technology in Cancer Research & Treatment},
  year = {2023},
  doi = {10.1177/15330338231175733}
}
Kostenlos starten →